CLASS II Drug recall · Reported 13 Aug 2014 · FDA Enforcement Report

Tetrahydrozoline HCL drum recalled by SST

SST is recalling Tetrahydrozoline HCL drum, distributed in California. The recall was initiated on 17 Jul 2014 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot: 168.862, Expiry: 6/2017
Quantity recalled1 Drum

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1517-2014
FDA event ID
68891
Recalling firm
SST, Clifton, NJ
Classification
Class II
Status
Terminated
Recall initiated
17 Jul 2014
FDA classified
6 Aug 2014
Reported
13 Aug 2014
Type
Voluntary: Firm initiated
Customers notified by
Telephone

Timeline

17 Jul 2014Recall initiated by company
6 Aug 2014Classified by FDA+20 days
13 Aug 2014Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations; Stored/dispensed in a non-GMP compliant warehouse at S.I.M.S., Italy.

Product as listed by the FDA

Tetrahydrozoline HCL, 16 kg drum. Societa Italiana Medicinali Scandicci (S.I.M.S.), Made in Italy. NDC 12660-0048 CAS #522-48-5

Where it was distributed

CA

California

Questions about this recall

Is Tetrahydrozoline HCL drum recalled?

Yes. SST recalled Tetrahydrozoline HCL drum on 17 Jul 2014. The recall is Class II and its status is Terminated. Recall number D-1517-2014.

Why was it recalled?

CGMP Deviations; Stored/dispensed in a non-GMP compliant warehouse at S.I.M.S., Italy.

Which lots are affected?

Lot: 168.862, Expiry: 6/2017

Where was it sold?

CA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.